Revised diagnostic testing for Zika, chikungunya, and dengue viruses in US Public Health Laboratories
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

i

Up-to-date Information

Up-to-Date Info: To find the latest CDC information on this topic go to: http://www.cdc.gov/zika/index.html

Revised diagnostic testing for Zika, chikungunya, and dengue viruses in US Public Health Laboratories

Filetype[PDF-973.25 KB]


Details Related Documents You May Also Like

Details:

  • Corporate Authors:
    National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Vector-Borne Diseases.
  • Description:
    Revision of: Updated diagnostic testing for Zika, chikungunya, and dengue viruses in US Public Health Laboratories. January 13, 2016.

    Memorandum

    Many countries in the Americas now have local transmission of multiple arboviruses that can cause febrile illness with rash, myalgia, or arthralgia. Therefore, laboratory testing has become even more important to confirm the etiology of these diseases. Zika, chikungunya, and dengue virus infections should all be considered for patients with acute fever, rash, myalgia, or arthralgia who have traveled within the previous 2 weeks to an area with ongoing transmission or are living in an area with ongoing transmission. In accordance with the Updated Interim Guidelines for Health Care Providers Caring for Pregnant Women and Women of Reproductive Age During Ongoing Zika Virus Transmission — United States, 2016 (http://www.cdc.gov/mmwr/volumes/65/wr/mm6505e2er.htm), this test algorithm now includes a recommendation to offer serologic testing to asymptomatic pregnant women with a history of travel to areas with local transmission of Zika virus or are living in an area with ongoing transmission. Laboratory evidence of recent chikungunya, dengue, or Zika virus infection is generally accomplished by testing serum to detect viral nucleic acid or virus- specific immunoglobulin (Ig) M and neutralizing antibodies. However, serological cross- reactivity may occur between Zika and other flaviviruses (e.g., dengue, yellow fever, St. Louis encephalitis, Japanese encephalitis, West Nile), so emphasis should be placed on molecular testing (RT-PCR) in acute specimens received from individuals with clinically compatible illness. Laboratory testing for Zika, chikungunya, and dengue viruses is currently available at CDC and several state and territory health departments.denvchikvzikv-testing-algorithm.pdf

  • Subjects:
  • Document Type:
    Pamphlet (or booklet)
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

Supporting Files

  • No Additional Files
More +

Related Documents

This document has replaced (most recent first):
  1. Updated diagnostic testing for Zika chikungunya and dengue viruses in US Public Health Laboratories
    Updated diagnostic testing for Zika, chikungunya, and dengue viruses in US Public Health Laboratories
    Filetype[PDF - 364.95 KB]
    :
    National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Vector-Borne Diseases.
    January 13, 2016
    Description:
    MemorandumMany countries in the Americas now have local transmission of multiple arboviruses that can cause febrile illness with rash, myalgia, or art...
    Status:
    superseded
    File Type:
    Filetype[PDF - 364.95 KB]
    File Type:
    Filetype[PDF - 364.95 KB]

You May Also Like

Checkout today's featured content at stacks.cdc.gov